Literature DB >> 2528320

Increases in helper inducer T cells and activated T cells in HTLV-I-associated myelopathy.

Y Itoyama1, J Kira, N Fujii, I Goto, N Yamamoto.   

Abstract

Using two-color flow cytometric analysis, we studied peripheral blood lymphocyte subsets in 15 patients with human T-cell lymphotropic virus type I-associated myelopathy. The percentage of CD4+ 4B4+ cells (helper inducer T cell) was significantly increased in the patients with the myelopathy, compared with 16 healthy control subjects who were seronegative for human T-cell lymphotropic virus type I. However, there was no difference in the percentage of CD4+ 2H4+ cells (suppressor inducer T cell) between the two groups. The ratio of CD4+ 4B4+ cells to CD4+ cells and CD4+ 4B4+ to CD4+ 2H4+ cells was also elevated in these patients. The percentage of CD4+ DR+ cells and CD8+ DR+ cells, both of which are phenotypically activated T cells, and the ratio of CD4+ DR+ cells to CD4+ cells and of CD8+ DR+ cells to CD8+ cells are also increased in the patients, compared with the control subjects. The percentage of CD4+ 4B4+ cells showed positive correlations with values of spontaneous proliferation of peripheral blood lymphocytes and serum IgG level in patients with the myelopathy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528320     DOI: 10.1002/ana.410260212

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

1.  Accumulation of human T-lymphotropic virus type I (HTLV-I)-infected cells in the cerebrospinal fluid during the exacerbation of HTLV-I-associated myelopathy.

Authors:  Daisuke Hayashi; Ryuji Kubota; Norihiro Takenouchi; Tomonori Nakamura; Fujio Umehara; Kimiyoshi Arimura; Shuji Izumo; Mitsuhiro Osame
Journal:  J Neurovirol       Date:  2008-11-12       Impact factor: 2.643

Review 2.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

3.  Phenotypes of mononuclear cell infiltrates in human central nervous system.

Authors:  Y Iwasaki; K Sako; I Tsunoda; Y Ohara
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 4.  The myeloneuropathies of Jamaica.

Authors:  O St Clair Morgan
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

5.  T-cell activation by autologous human T-cell leukemia virus type I-infected T-cell clones.

Authors:  K W Wucherpfennig; P Höllsberg; J H Richardson; D Benjamin; D A Hafler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

6.  Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis.

Authors:  A Ali; S Patterson; K Cruickshank; P Rudge; A G Dalgleish; S C Knight
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

7.  Neuroaxonal dystrophy in HTLV-1-associated myelopathy/tropical spastic paraparesis: neuropathologic and neuroimmunologic correlations.

Authors:  E Wu; D W Dickson; S Jacobson; C S Raine
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  The presence of HTLV-I proviral DNA in the central nervous system of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.

Authors:  J Kira
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

9.  Concomitant augmentation of CD4+ CD29+ helper inducer and diminution of CD4+ CD45RA+ suppressor inducer subset in patients infected with human T cell lymphotropic virus types I or II.

Authors:  R B Lal; D L Rudolph; D S Schmid; M D Lairmore
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

10.  Infiltration of helper/inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection.

Authors:  Y Iwasaki; Y Ohara; I Kobayashi; S Akizuki
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.